董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sam Van | 男 | Director | 47 | 未披露 | 未持股 | 2025-09-02 |
| Patrick NJ Schnegelsberg | 男 | Chief Executive Officer and Director | 61 | 40.00万美元 | 未持股 | 2025-09-02 |
| Richard Fang | 男 | Director | 58 | 未披露 | 未持股 | 2025-09-02 |
| Chris Hsieh | 男 | Director | 48 | 未披露 | 未持股 | 2025-09-02 |
| George Ye | 男 | Director | 49 | 未披露 | 未持股 | 2025-09-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick NJ Schnegelsberg | 男 | Chief Executive Officer and Director | 61 | 40.00万美元 | 未持股 | 2025-09-02 |
| Bernard Skaggs | 男 | Chief Financial Officer | 62 | 20.00万美元 | 未持股 | 2025-09-02 |
| Matt Schuster | 男 | Chief Operating Officer | 44 | 22.00万美元 | 未持股 | 2025-09-02 |
董事简历
中英对照 | 中文 | 英文- Sam Van
-
自本招股说明书发布之日起，Sam Van一直担任我们的董事。Van先生目前担任Deltec Investment Advisers Limited的董事总经理兼负责人，自2018年以来，他一直领导美国和国际交易所上市咨询业务的工作。2019年，范先生受美国政府外国投资委员会CFIUS委托担任联席主席和受托人成员，负责监督投资项目的清算。此前，Van先生于2012年至2017年担任金融业监管局的副负责人，担任过各种职务，包括交易和金融合规检查、销售实践以及金融风险监督和运营监管。在Van于2001年至2011年担任纽约证券交易所董事期间，Van先生负责新业务开发，专门研究整个亚洲的新兴资本市场。范先生在纽约证券交易所获得了60多家公司的担保，总市值超过70亿美元。Van先生获得了圣约翰大学的金融学士学位和康奈尔大学的MBA学位。
Sam Van will serve as a director upon consummation of the Initial Public Offering. Sam has been the founder and CEO of SRO Partners since May, 2024. He served as the Head of Advisory Services and Senior Vice President for Freedom U.S. Markets, a dividing of Freedom Holding Corp (Nasdaq: FRHC) from September 2022 to May 2024,and as president and a director of Deltec Investment Adviser Limited from May 2017 to September 2022. Earlier in his career, Sam held senior roles at the New York Stock Exchange, including Director of International Listings, where he originated over 60 listings, and as a Senior Examiner in NYSE Regulation. He has also served as a director and as audit committee chair and a member of the nominating committee of Reed's Inc. since October 2024, as a director of Relm Insurance Limited (Bermuda) since January 2019 and as a director for Phoenix Motor, Inc. from June 2022 to May 2024. Sam began his career as an examiner with FINRA. He holds an MBA from Cornell University's Johnson School of BPicard Medical, Inc.iness and a BS in Finance from St. John's University. - 自本招股说明书发布之日起，Sam Van一直担任我们的董事。Van先生目前担任Deltec Investment Advisers Limited的董事总经理兼负责人，自2018年以来，他一直领导美国和国际交易所上市咨询业务的工作。2019年，范先生受美国政府外国投资委员会CFIUS委托担任联席主席和受托人成员，负责监督投资项目的清算。此前，Van先生于2012年至2017年担任金融业监管局的副负责人，担任过各种职务，包括交易和金融合规检查、销售实践以及金融风险监督和运营监管。在Van于2001年至2011年担任纽约证券交易所董事期间，Van先生负责新业务开发，专门研究整个亚洲的新兴资本市场。范先生在纽约证券交易所获得了60多家公司的担保，总市值超过70亿美元。Van先生获得了圣约翰大学的金融学士学位和康奈尔大学的MBA学位。
- Sam Van will serve as a director upon consummation of the Initial Public Offering. Sam has been the founder and CEO of SRO Partners since May, 2024. He served as the Head of Advisory Services and Senior Vice President for Freedom U.S. Markets, a dividing of Freedom Holding Corp (Nasdaq: FRHC) from September 2022 to May 2024,and as president and a director of Deltec Investment Adviser Limited from May 2017 to September 2022. Earlier in his career, Sam held senior roles at the New York Stock Exchange, including Director of International Listings, where he originated over 60 listings, and as a Senior Examiner in NYSE Regulation. He has also served as a director and as audit committee chair and a member of the nominating committee of Reed's Inc. since October 2024, as a director of Relm Insurance Limited (Bermuda) since January 2019 and as a director for Phoenix Motor, Inc. from June 2022 to May 2024. Sam began his career as an examiner with FINRA. He holds an MBA from Cornell University's Johnson School of BPicard Medical, Inc.iness and a BS in Finance from St. John's University.
- Patrick NJ Schnegelsberg
-
Patrick NJ Schnegelsberg，担任首席执行官。Patrick拥有超过25年的行政领导经验，并在医疗器械领域拥有良好的业绩记录。2022年12月至2023年7月，Patrick担任Syntach AB的首席执行官；2012年7月至2021年3月，担任Occlutech Group及其子公司的首席运营官兼首席执行官。他还曾在欧洲和美国的医疗和生物技术初创公司担任c级职位，包括一家在美国上市的生物技术公司。在医疗设备indPicard medical， Inc.try工作之前，Patrick在华尔街的买方和卖方公司担任董事级别的职位。帕特里克在麻省理工学院进行了广泛的分子生物学研究，毕业于哈佛医学院和克拉克大学。他目前担任Acorai AB咨询委员会的独立主席，也是Scandinavian Real Heart的前董事会成员。
Patrick NJ Schnegelsberg serves as Chief Executive Officer. Patrick has over 25 years of executive leadership experience and a proven track record in the medical device sector. Patrick served as CEO of Syntach AB from December 2022 to July 2023, and as COO and CEO with the Occlutech Group and its subsidiaries from July 2012 to March 2021. He has also held C-level positions with European and U.S. med- and biotech start-ups, including a U.S.-listed biotech company. Before working in the medical device indPicard Medical, Inc.try, Patrick held director-level positions with buy- and sell-side firms on Wall Street. Patrick conducted extensive research in molecular biology at MIT and graduated from Harvard Medical School and Clark University. He currently serves as independent Chairman on the advisory board of Acorai AB and is a former board member of Scandinavian Real Heart. - Patrick NJ Schnegelsberg，担任首席执行官。Patrick拥有超过25年的行政领导经验，并在医疗器械领域拥有良好的业绩记录。2022年12月至2023年7月，Patrick担任Syntach AB的首席执行官；2012年7月至2021年3月，担任Occlutech Group及其子公司的首席运营官兼首席执行官。他还曾在欧洲和美国的医疗和生物技术初创公司担任c级职位，包括一家在美国上市的生物技术公司。在医疗设备indPicard medical， Inc.try工作之前，Patrick在华尔街的买方和卖方公司担任董事级别的职位。帕特里克在麻省理工学院进行了广泛的分子生物学研究，毕业于哈佛医学院和克拉克大学。他目前担任Acorai AB咨询委员会的独立主席，也是Scandinavian Real Heart的前董事会成员。
- Patrick NJ Schnegelsberg serves as Chief Executive Officer. Patrick has over 25 years of executive leadership experience and a proven track record in the medical device sector. Patrick served as CEO of Syntach AB from December 2022 to July 2023, and as COO and CEO with the Occlutech Group and its subsidiaries from July 2012 to March 2021. He has also held C-level positions with European and U.S. med- and biotech start-ups, including a U.S.-listed biotech company. Before working in the medical device indPicard Medical, Inc.try, Patrick held director-level positions with buy- and sell-side firms on Wall Street. Patrick conducted extensive research in molecular biology at MIT and graduated from Harvard Medical School and Clark University. He currently serves as independent Chairman on the advisory board of Acorai AB and is a former board member of Scandinavian Real Heart.
- Richard Fang
-
Richard Fang，是投资于医疗器械领域的投资集团Hunniwell Lake Ventures LLC（“HLV”）的创始人和管理合伙人。HLV成立于2019年。HLV最近通过Picard Medical，Inc.收购了SynCardia Systems，后者现已成为HLV公司家族的一部分。除了HLV，Richard于2005年在加州创立了微创手术器械公司Reach Surgical。在15年的时间里，他推动Reach Surgical成长为一个行业领先的品牌，业务遍及六大洲。在此期间，他监督了包括数十个SKU在内的三个产品线的开发、制造、营销和销售。他在Reach Surgical任职期间，在最近将该公司出售给一位私募股权买家的交易中达到了高潮。Richard在医疗器械行业拥有超过20年的专业实践经验，其中包括美国强生。他拥有辛辛那提大学的MBA学位，以及印第安纳波利斯普渡大学的物理学博士学位。作为一名科幻迷，他相信铁人心脏，并有一个愿景，即SynCardia TAH将成为心脏移植的首选替代品。
Richard Fang, Ph.D. is a founder and managing partner of HunniPicard Medical, Inc.ll Lake Ventures LLC ("HLV"), an investment group investing in the medical device space. HLV was formed in 2019. HLV, through Picard Medical, Inc., recently acquired SynCardia Systems, which is now part of the HLV family of companies. In addition to HLV, Richard founded Reach Surgical, a minimally invasive surgical instruments company in California in 2005. Over a 15-year period, he drove the growth of Reach Surgical into an indPicard Medical, Inc.try-leading brand with presence on six continents. During that time, he oversaw the development, manufacturing, marketing, and sales of three product lines including dozens of SKPicard Medical, Inc.. His tenure with Reach Surgical culminated in the recent sale of the company to a private equity buyer. Richard has over 20 years of professional hands-on experience in the medical device indPicard Medical, Inc.try, including Johnson & Johnson in the United States. He has an MBA from the University of Cincinnati, as Picard Medical, Inc.ll as a Ph.D. in Physics from Purdue University in Indianapolis. - Richard Fang，是投资于医疗器械领域的投资集团Hunniwell Lake Ventures LLC（“HLV”）的创始人和管理合伙人。HLV成立于2019年。HLV最近通过Picard Medical，Inc.收购了SynCardia Systems，后者现已成为HLV公司家族的一部分。除了HLV，Richard于2005年在加州创立了微创手术器械公司Reach Surgical。在15年的时间里，他推动Reach Surgical成长为一个行业领先的品牌，业务遍及六大洲。在此期间，他监督了包括数十个SKU在内的三个产品线的开发、制造、营销和销售。他在Reach Surgical任职期间，在最近将该公司出售给一位私募股权买家的交易中达到了高潮。Richard在医疗器械行业拥有超过20年的专业实践经验，其中包括美国强生。他拥有辛辛那提大学的MBA学位，以及印第安纳波利斯普渡大学的物理学博士学位。作为一名科幻迷，他相信铁人心脏，并有一个愿景，即SynCardia TAH将成为心脏移植的首选替代品。
- Richard Fang, Ph.D. is a founder and managing partner of HunniPicard Medical, Inc.ll Lake Ventures LLC ("HLV"), an investment group investing in the medical device space. HLV was formed in 2019. HLV, through Picard Medical, Inc., recently acquired SynCardia Systems, which is now part of the HLV family of companies. In addition to HLV, Richard founded Reach Surgical, a minimally invasive surgical instruments company in California in 2005. Over a 15-year period, he drove the growth of Reach Surgical into an indPicard Medical, Inc.try-leading brand with presence on six continents. During that time, he oversaw the development, manufacturing, marketing, and sales of three product lines including dozens of SKPicard Medical, Inc.. His tenure with Reach Surgical culminated in the recent sale of the company to a private equity buyer. Richard has over 20 years of professional hands-on experience in the medical device indPicard Medical, Inc.try, including Johnson & Johnson in the United States. He has an MBA from the University of Cincinnati, as Picard Medical, Inc.ll as a Ph.D. in Physics from Purdue University in Indianapolis.
- Chris Hsieh
-
Chris Hsieh是HLV的管理合伙人，自2021年1月起担任该职务。自2021年4月起，他还担任香港领先的女性护理和生育医疗服务提供商The Women's Clinic Group的首席执行官。在Chris担任现任职务之前，Chris是深圳IVPS科技的首席执行官和顾问。他在投资银行业度过了20多年，2013年至2019年担任高盛高盛的董事总经理，在高盛Sachs之前曾任职于摩根大通。在他的银行业生涯中，克里斯领导了亚洲一些规模最大、最引人注目的并购交易和IPO。克里斯在芝加哥大学获得经济学学士学位。
Chris Hsieh is a managing partner at HLV, a role he has held since January 2021. Since April 2021, he has also served as the CEO of The Women's Clinic Group, a leading woman-care and fertility medical services provider in Hong Kong. Prior to Chris' current roles, Chris was CEO and Advisor to Shenzhen IVPS Technology. He spent over 20 years in the investment banking indPicard Medical, Inc.try and was a Managing Director at Goldman Sachs from 2013 to 2019 and worked at J.P. Morgan prior to Goldman Sachs. During his banking career, Chris had led some of the largest and highest-profile merger and acquisition transactions and IPOs in Asia. Chris received his Bachelor's degree in Economics from The University of Chicago. Chris has resigned as a director of the Company, effective at the consummation of this Offering. - Chris Hsieh是HLV的管理合伙人，自2021年1月起担任该职务。自2021年4月起，他还担任香港领先的女性护理和生育医疗服务提供商The Women's Clinic Group的首席执行官。在Chris担任现任职务之前，Chris是深圳IVPS科技的首席执行官和顾问。他在投资银行业度过了20多年，2013年至2019年担任高盛高盛的董事总经理，在高盛Sachs之前曾任职于摩根大通。在他的银行业生涯中，克里斯领导了亚洲一些规模最大、最引人注目的并购交易和IPO。克里斯在芝加哥大学获得经济学学士学位。
- Chris Hsieh is a managing partner at HLV, a role he has held since January 2021. Since April 2021, he has also served as the CEO of The Women's Clinic Group, a leading woman-care and fertility medical services provider in Hong Kong. Prior to Chris' current roles, Chris was CEO and Advisor to Shenzhen IVPS Technology. He spent over 20 years in the investment banking indPicard Medical, Inc.try and was a Managing Director at Goldman Sachs from 2013 to 2019 and worked at J.P. Morgan prior to Goldman Sachs. During his banking career, Chris had led some of the largest and highest-profile merger and acquisition transactions and IPOs in Asia. Chris received his Bachelor's degree in Economics from The University of Chicago. Chris has resigned as a director of the Company, effective at the consummation of this Offering.
- George Ye
-
George Ye，曾在爱德华兹生命科学（NYSE：EW）担任多个职务，包括2019年4月至2024年10月担任大中华区高级副总裁兼总经理，2016年10月至2019年4月担任日本外科副总裁兼总经理，205年4月至2016年9月担任日本和亚太战略高级总监。此前，George曾在雅培和强生担任过多个职务。乔治获得了西北大学化学工程学理学学士学位和MBA学位。
George Ye,served in varioPicard Medical, Inc. roles at Edwards Lifesciences (NYSE: EW), including Senior Vice President and General Manager, Greater China Region from April 2019 to October 2024, Vice President and General Manager, Japan Surgical, from October 2016 to April 2019, and Senior Director, Japan and Asia Pacific Strategy from April 205 to September 2016. Prior, George held varioPicard Medical, Inc. roles at Abbott Laboratories and Johnson & Johnson. George received his Bachelor of Science in Chemical Engineering and his MBA from NorthPicard Medical, Inc.stern University. - George Ye，曾在爱德华兹生命科学（NYSE：EW）担任多个职务，包括2019年4月至2024年10月担任大中华区高级副总裁兼总经理，2016年10月至2019年4月担任日本外科副总裁兼总经理，205年4月至2016年9月担任日本和亚太战略高级总监。此前，George曾在雅培和强生担任过多个职务。乔治获得了西北大学化学工程学理学学士学位和MBA学位。
- George Ye,served in varioPicard Medical, Inc. roles at Edwards Lifesciences (NYSE: EW), including Senior Vice President and General Manager, Greater China Region from April 2019 to October 2024, Vice President and General Manager, Japan Surgical, from October 2016 to April 2019, and Senior Director, Japan and Asia Pacific Strategy from April 205 to September 2016. Prior, George held varioPicard Medical, Inc. roles at Abbott Laboratories and Johnson & Johnson. George received his Bachelor of Science in Chemical Engineering and his MBA from NorthPicard Medical, Inc.stern University.
高管简历
中英对照 | 中文 | 英文- Patrick NJ Schnegelsberg
Patrick NJ Schnegelsberg，担任首席执行官。Patrick拥有超过25年的行政领导经验，并在医疗器械领域拥有良好的业绩记录。2022年12月至2023年7月，Patrick担任Syntach AB的首席执行官；2012年7月至2021年3月，担任Occlutech Group及其子公司的首席运营官兼首席执行官。他还曾在欧洲和美国的医疗和生物技术初创公司担任c级职位，包括一家在美国上市的生物技术公司。在医疗设备indPicard medical， Inc.try工作之前，Patrick在华尔街的买方和卖方公司担任董事级别的职位。帕特里克在麻省理工学院进行了广泛的分子生物学研究，毕业于哈佛医学院和克拉克大学。他目前担任Acorai AB咨询委员会的独立主席，也是Scandinavian Real Heart的前董事会成员。
Patrick NJ Schnegelsberg serves as Chief Executive Officer. Patrick has over 25 years of executive leadership experience and a proven track record in the medical device sector. Patrick served as CEO of Syntach AB from December 2022 to July 2023, and as COO and CEO with the Occlutech Group and its subsidiaries from July 2012 to March 2021. He has also held C-level positions with European and U.S. med- and biotech start-ups, including a U.S.-listed biotech company. Before working in the medical device indPicard Medical, Inc.try, Patrick held director-level positions with buy- and sell-side firms on Wall Street. Patrick conducted extensive research in molecular biology at MIT and graduated from Harvard Medical School and Clark University. He currently serves as independent Chairman on the advisory board of Acorai AB and is a former board member of Scandinavian Real Heart.- Patrick NJ Schnegelsberg，担任首席执行官。Patrick拥有超过25年的行政领导经验，并在医疗器械领域拥有良好的业绩记录。2022年12月至2023年7月，Patrick担任Syntach AB的首席执行官；2012年7月至2021年3月，担任Occlutech Group及其子公司的首席运营官兼首席执行官。他还曾在欧洲和美国的医疗和生物技术初创公司担任c级职位，包括一家在美国上市的生物技术公司。在医疗设备indPicard medical， Inc.try工作之前，Patrick在华尔街的买方和卖方公司担任董事级别的职位。帕特里克在麻省理工学院进行了广泛的分子生物学研究，毕业于哈佛医学院和克拉克大学。他目前担任Acorai AB咨询委员会的独立主席，也是Scandinavian Real Heart的前董事会成员。
- Patrick NJ Schnegelsberg serves as Chief Executive Officer. Patrick has over 25 years of executive leadership experience and a proven track record in the medical device sector. Patrick served as CEO of Syntach AB from December 2022 to July 2023, and as COO and CEO with the Occlutech Group and its subsidiaries from July 2012 to March 2021. He has also held C-level positions with European and U.S. med- and biotech start-ups, including a U.S.-listed biotech company. Before working in the medical device indPicard Medical, Inc.try, Patrick held director-level positions with buy- and sell-side firms on Wall Street. Patrick conducted extensive research in molecular biology at MIT and graduated from Harvard Medical School and Clark University. He currently serves as independent Chairman on the advisory board of Acorai AB and is a former board member of Scandinavian Real Heart.
- Bernard Skaggs
Bernard Skaggs，2023年11月被任命为首席财务官。伯纳德在金融和会计领域拥有超过30年的经验。在担任首席财务官之前，Bernard于2023年2月至2023年11月期间担任Picard Medical，Inc.财务总监。在加入SynCardia之前，Bernard于2022年6月至2023年2月担任Golden 福泰制药 Corporation的财务总监，于2020年5月至2022年6月担任Asarco LLC的工厂总监，于2019年12月至2020年5月担任Experis的财务总监顾问，于2017年12月至2019年9月担任Embraer Embraer Aero Seating Technologies（Embraer的子公司）的工厂总监，并于2015年4月至2017年12月担任癌症预防制药的会计经理。伯纳德的职业生涯始于德勤，曾在美国和日本担任过一系列职务，是一名美国陆军退伍军人。伯纳德在亚利桑那大学获得本科学位，在凤凰城大学获得会计学硕士学位，在雷鸟全球管理学院获得MBA学位。
Bernard Skaggs was appointed as Chief Financial Officer in November 2023. Bernard has over 30 years of experience in finance and accounting. Prior to his role as Chief Financial Officer, Bernard served as Controller from February 2023 to November 2023. Prior to his time at SynCardia, Bernard was Controller at Golden Vertex Corporation from June 2022 to February 2023, Plant Controller at Asarco LLC from May 2020 to June 2022, Controller Consultant at Experis from December 2019 to May 2020, Plant Controller at Embraer Aero Seating Technologies, a subsidiary of Embraer, from December 2017 to September 2019, and Accounting Manager at Cancer Prevention Pharmaceuticals from April 2015 to December 2017. Bernard started his career with Deloitte and has held a range of positions in the United States and Japan and is a U.S. Army Veteran. Bernard received his undergraduate degree from the University of Arizona, a master's degree in Accountancy from the University of Phoenix, and an MBA from the Thunderbird School of Global Management.- Bernard Skaggs，2023年11月被任命为首席财务官。伯纳德在金融和会计领域拥有超过30年的经验。在担任首席财务官之前，Bernard于2023年2月至2023年11月期间担任Picard Medical，Inc.财务总监。在加入SynCardia之前，Bernard于2022年6月至2023年2月担任Golden 福泰制药 Corporation的财务总监，于2020年5月至2022年6月担任Asarco LLC的工厂总监，于2019年12月至2020年5月担任Experis的财务总监顾问，于2017年12月至2019年9月担任Embraer Embraer Aero Seating Technologies（Embraer的子公司）的工厂总监，并于2015年4月至2017年12月担任癌症预防制药的会计经理。伯纳德的职业生涯始于德勤，曾在美国和日本担任过一系列职务，是一名美国陆军退伍军人。伯纳德在亚利桑那大学获得本科学位，在凤凰城大学获得会计学硕士学位，在雷鸟全球管理学院获得MBA学位。
- Bernard Skaggs was appointed as Chief Financial Officer in November 2023. Bernard has over 30 years of experience in finance and accounting. Prior to his role as Chief Financial Officer, Bernard served as Controller from February 2023 to November 2023. Prior to his time at SynCardia, Bernard was Controller at Golden Vertex Corporation from June 2022 to February 2023, Plant Controller at Asarco LLC from May 2020 to June 2022, Controller Consultant at Experis from December 2019 to May 2020, Plant Controller at Embraer Aero Seating Technologies, a subsidiary of Embraer, from December 2017 to September 2019, and Accounting Manager at Cancer Prevention Pharmaceuticals from April 2015 to December 2017. Bernard started his career with Deloitte and has held a range of positions in the United States and Japan and is a U.S. Army Veteran. Bernard received his undergraduate degree from the University of Arizona, a master's degree in Accountancy from the University of Phoenix, and an MBA from the Thunderbird School of Global Management.
- Matt Schuster
马特·舒斯特，于2023年11月被任命为首席运营官。在担任这一职务之前，Matt在2023年5月至2023年11月期间担任SynCardia的研发总监。从2021年1月到2023年5月，Matt在罗氏担任过多个职务，包括工程承包商、员工机械工程师和系统开发主管。在担任罗氏之前，Matt曾于2018年4月至2021年1月担任SynCardia的制造和设施总监。他在SynCardia的开发项目中发挥了关键作用，包括更小尺寸的50CC全人工心脏和下一代气动驱动器。Matt在北亚利桑那大学获得机械工程学士学位。
Matt Schuster, was appointed as Chief Operating Officer in November 2023. Prior to this role, Matt was the Director of Research and Development for SynCardia from May 2023 to November 2023. From January 2021 through May 2023, Matt held varioPicard Medical, Inc. roles with Roche, including as an Engineering Contractor, Staff Mechanical Engineer, and Systems Development Lead. Prior to his roles at Roche, Matt was the Director of Manufacturing and Facilities at SynCardia from April 2018 to January 2021. He has played a key role in development projects for SynCardia, including the smaller sized 50cc total artificial heart and next generation pneumatic driver. Matt received his Bachelor's degree in Mechanical Engineering from Northern Arizona University.- 马特·舒斯特，于2023年11月被任命为首席运营官。在担任这一职务之前，Matt在2023年5月至2023年11月期间担任SynCardia的研发总监。从2021年1月到2023年5月，Matt在罗氏担任过多个职务，包括工程承包商、员工机械工程师和系统开发主管。在担任罗氏之前，Matt曾于2018年4月至2021年1月担任SynCardia的制造和设施总监。他在SynCardia的开发项目中发挥了关键作用，包括更小尺寸的50CC全人工心脏和下一代气动驱动器。Matt在北亚利桑那大学获得机械工程学士学位。
- Matt Schuster, was appointed as Chief Operating Officer in November 2023. Prior to this role, Matt was the Director of Research and Development for SynCardia from May 2023 to November 2023. From January 2021 through May 2023, Matt held varioPicard Medical, Inc. roles with Roche, including as an Engineering Contractor, Staff Mechanical Engineer, and Systems Development Lead. Prior to his roles at Roche, Matt was the Director of Manufacturing and Facilities at SynCardia from April 2018 to January 2021. He has played a key role in development projects for SynCardia, including the smaller sized 50cc total artificial heart and next generation pneumatic driver. Matt received his Bachelor's degree in Mechanical Engineering from Northern Arizona University.